Security
Apollomics Inc. Warrant · APLMW
APLMWNASDAQWarrantCurrentCIK 1944885Updated Oct 6, 2026
APLMW price & chart
Loading TradingView…
NASDAQ:APLMW on TradingView ↗About the company
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.
In the news
No coverage from other publishers is available.
Recent filings
424B3 filing
D filing
Items 06b
SCHEDULE 13D/A - filed by Chen Yi-Kuei regarding Apollomics Inc.
6-K filing
6-K filing
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
cash flow · annual statements
| Line item | Q2 2023 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Profit or LossUSD | — | -53,858,000Source | -172,601,000Source | -240,811,000Source | -94,797,000Source |
| Cash flows from financing activities: | |||||
| Dividends paid | — | —Source | —Source | —Source | —Source |
| Additional Financial Items | |||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | — | 0Source | 0Source | 0Source | 0Source |
| AdjustmentsForFinanceCostsUSD | — | 193,000Source | 122,000Source | 93,000Source | 83,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | 10,926,000Source | 12,685,000Source | 3,582,000Source | 8,122,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | -258,000Source | 663,000Source | — |
| InterestPaidClassifiedAsFinancingActivitiesUSD | — | 193,000Source | 122,000Source | 93,000Source | 83,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | 259,000Source | 10,000Source | 1,000Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | 170,000Source | 444,000Source | 593,000Source | 528,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | — | 4,000Source | 58,000Source | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | — | 7,500,000Source |
| Goodwill | —Source | — | — | — | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||
| AdministrativeExpenseUSD | 17,768,000Source | 20,641,000Source | 9,947,000Source | 15,291,000Source |
| BasicEarningsLossPerShareUSD per share | -52.8Source | -2.32Source | -0.62Source | -0.23Source |
| CurrentTaxExpenseIncomeUSD | 259,000Source | 10,000Source | 1,000Source | 1,000Source |
| DeferredTaxExpenseIncomeUSD | 0Source | 0Source | 0Source | 0Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | 0Source | 0Source | 0Source | 0Source |
| DepreciationRightofuseAssetsUSD | 289,000Source | 587,000Source | 593,000Source | 528,000Source |
| DilutedEarningsLossPerShareUSD per share | -52.8Source | -2.32Source | -0.62Source | -0.23Source |
| EmployeeBenefitsExpenseUSD | 19,556,000Source | 23,540,000Source | 19,210,000Source | 27,742,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 10,926,000Source | 12,685,000Source | 3,582,000Source | 8,122,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedUSD | 67,000Source | 122,000Source | 96,000Source | 56,000Source |
| FinanceCostsUSD | 179,000Source | 150,000Source | 93,000Source | 83,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | 13,000,000Source | 0Source | 0Source | 3,000,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 259,000Source | 10,000Source | 1,000Source | 1,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 179,000Source | 150,000Source | 93,000Source | 83,000Source |
| OtherIncomeUSD | 1,489,000Source | 1,217,000Source | 1,447,000Source | 1,054,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | 300,000Source | 499,000Source | 662,000Source | 749,000Source |
| ProfitLossBeforeTaxUSD | -53,599,000Source | -172,591,000Source | -240,810,000Source | -94,796,000Source |
| ProfitLossFromOperatingActivitiesUSD | — | — | 976,000Source | — |
| ResearchAndDevelopmentExpenseUSD | 24,566,000Source | 34,193,000Source | 35,457,000Source | 35,568,000Source |
| RevenueFromInterestUSD | 480,000Source | 753,000Source | 431,000Source | 467,000Source |
Offerings
Registration 333-294154
Filing attachments
d133013dex991.htm · 6-K · 2026-08-12
Exhibit 99.1 Apollomics Announces $10 Million Private Placement Transaction FOSTER CITY, CALIF. - August 11, 2026 - Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Plac…
Read attachment ↗d31896dex991.htm · 6-K · 2026-07-14
Exhibit 99.1 Apollomics Regains Full Compliance with Nasdaq Listing Requirements FOSTER CITY, CALIF. - July 13, 2026 - Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained complia…
Read attachment ↗d137400dex991.htm · 6-K · 2026-06-24
Exhibit 99.1 Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia FOSTER CITY, CALIF. - June 24, 2026 - Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the “Notice”) from The Nasdaq Stock Ma…
Read attachment ↗aplm-ex99_1.htm · 6-K · 2026-04-27
Exhibit 99.1 Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress ▪ Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. ▪ To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials. ▪ Phase 2/3 IND submission for development of vebreltinib in combination with an E…
Read attachment ↗d142784dex991.htm · 6-K · 2026-04-01
Exhibit 99.1 PRESS RELEASE Apollomics Inc. Announces $2.0 Million Bridge Financing FOSTER CITY, Calif., April 1, 2026 (GLOBE NEWSWIRE) - Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr. Hung-Wen (Howard) Chen, the Company’s Chairman and Chief Executive Officer, on March 30, 2026. The $2.0 million in proceeds from the Note are intended to provide the Company with …
Read attachment ↗